Fig. 2: AID-deficient CLL cells have lower B220 and higher BCR signaling.
From: Loss of AID exacerbates the malignant progression of CLL
A Representative flow cytometry plots of B220 expression in B cells and CLL cells from the peripheral blood of Eμ-TCL1 and AID−/−/Eμ-TCL1 mice at 2, 4, and 6 months of age. Splenocytes were stained with CD19-APC-Cy7, B220-Alexa 488, and CD5-APC and analyzed for B220+/CD5− B cells and B220low/CD5+ CLL cells on gated CD19+ populations. B, C CLL cells were examined for the expression of B220 in the peripheral blood (B) and spleens (C) of 6-month-old Eμ-TCL1 (n = 11) and AID−/−/Eμ-TCL1 (n = 11) mice. D CLL cells purified from the spleens of Eμ-TCL1 and AID−/−/Eμ-TCL1 mice were activated with anti-mouse IgM F(ab’)2 for the indicated times and lysed for immunoblot analyses of the indicated proteins. E CLL cells purified from the spleens of Eμ-TCL1 (n = 5) and AID−/−/Eμ-TCL1 (n = 6) mice were stimulated with 20 μg/mL LPS for 3 days and examined for phospho-SYK by flow cytometry. F CLL cells purified from the spleens of Eμ-TCL1 (n = 5) and AID−/−/Eμ-TCL1 (n = 6) mice were stimulated with 20 μg/mL LPS for 2 days, subsequently treated with 4 μM ibrutinib for 1 day, and subjected to XTT assays. Percentage growth was determined by comparing cells treated with ibrutinib with those that were untreated.
